Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Study of Dual Specificity CD19 and CD22 Chimeric Antigen Receptor T Cell Therapy in Relapsed or Refractory Acute B Lymphoblastic Leukemia

NCT04094766 is registered in ClinicalTrials.gov with Second Affiliated Hospital of Xi'an Jiaotong University as lead sponsor.

NCT NCT04094766
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04094766 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Study of Dual Specificity CD19 and CD22 Chimeric Antigen Receptor T Cell Therapy in Relapsed or Refractory Acute B Lymphoblastic Leukemia
Lead sponsor
Second Affiliated Hospital of Xi'an Jiaotong University
Phase
Phase 1
Overall status
Withdrawn
Start date
August 1, 2017
Completion date
August 30, 2020
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

refractory b acute lymphoblastic leukemia, relapse b acute lymphoblastic leukemia